Robert Kralovics
Robert Kralovics
Principal Investigator, Medical University of Vienna
Verified email at meduniwien.ac.at
Title
Cited by
Cited by
Year
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics, F Passamonti, AS Buser, SS Teo, R Tiedt, JR Passweg, ...
New England Journal of Medicine 352 (17), 1779-1790, 2005
37422005
Somatic mutations of calreticulin in myeloproliferative neoplasms
T Klampfl, H Gisslinger, AS Harutyunyan, H Nivarthi, E Rumi, JD Milosevic, ...
New England Journal of Medicine 369 (25), 2379-2390, 2013
15822013
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease
A Zimprich, A Benet-Pagès, W Struhal, E Graf, SH Eck, MN Offman, ...
The American Journal of Human Genetics 89 (1), 168-175, 2011
7022011
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ...
Blood 123 (10), 1544-1551, 2014
5002014
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
P Lundberg, A Karow, R Nienhold, R Looser, H Hao-Shen, I Nissen, ...
Blood 123 (14), 2220-2228, 2014
4592014
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
R Kralovics, Y Guan, JT Prchal
Experimental hematology 30 (3), 229-236, 2002
3752002
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
D Olcaydu, A Harutyunyan, R Jäger, T Berg, B Gisslinger, I Pabinger, ...
Nature genetics 41 (4), 450-454, 2009
3552009
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
D Pietra, S Li, A Brisci, F Passamonti, E Rumi, A Theocharides, M Ferrari, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1686-1689, 2008
3412008
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
R Kralovics, SS Teo, S Li, A Theocharides, AS Buser, A Tichelli, ...
Blood 108 (4), 1377-1380, 2006
3112006
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
E Lippert, M Boissinot, R Kralovics, F Girodon, I Dobo, V Praloran, ...
Blood 108 (6), 1865-1867, 2006
2832006
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
H Gisslinger, M Gotic, J Holowiecki, M Penka, J Thiele, HM Kvasnicka, ...
Blood 121 (10), 1720-1728, 2013
2642013
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
R Kralovics, SS Teo, AS Buser, M Brutsche, R Tiedt, A Tichelli, ...
Blood 106 (10), 3374-3376, 2005
2382005
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
W Vainchenker, R Kralovics
Blood, The Journal of the American Society of Hematology 129 (6), 667-679, 2017
2292017
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
I Chachoua, C Pecquet, M El-Khoury, H Nivarthi, RI Albu, C Marty, ...
Blood, The Journal of the American Society of Hematology 127 (10), 1325-1335, 2016
2182016
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders
R Kralovics, AS Buser, SS Teo, J Coers, A Tichelli, APC van der Maas, ...
Blood 102 (5), 1869-1871, 2003
1862003
p53 lesions in leukemic transformation
A Harutyunyan, T Klampfl, M Cazzola, R Kralovics
New England Journal of Medicine 364 (5), 488-490, 2011
1842011
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
M Cazzola, R Kralovics
Blood 123 (24), 3714-3719, 2014
1772014
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
C Marty, C Pecquet, H Nivarthi, M El-Khoury, I Chachoua, M Tulliez, ...
Blood 127 (10), 1317-1324, 2016
1732016
Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line
P Essletzbichler, T Konopka, F Santoro, D Chen, BV Gapp, R Kralovics, ...
Genome research 24 (12), 2059-2065, 2014
1692014
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
T Klampfl, A Harutyunyan, T Berg, B Gisslinger, M Schalling, K Bagienski, ...
Blood, The Journal of the American Society of Hematology 118 (1), 167-176, 2011
1632011
The system can't perform the operation now. Try again later.
Articles 1–20